HIV Drugs Market Poised to Hit $41.55 Billion by 2029 with Accelerating Growth Trends

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

HIV Drugs Market Size Growth Forecast: What to Expect by 2025?
The market size of HIV drugs has been experiencing a consistent surge in recent years. It is projected to increase from $35.33 billion in 2024 to $36.55 billion in 2025, with a compound annual growth rate (CAGR) of 3.5%. The historic period's growth is credited to enhanced government assistance and initiatives, an escalation in healthcare spending, an increase in research and development funding for HIV, a higher rate of HIV infection, and economic growth in emerging markets.

How Will the HIV Drugs Market Size Evolve and Grow by 2029?
In the coming years, the market size for HIV drugs is anticipated to experience consistent growth, rising to "$41.55 billion in 2029, with a compound annual growth rate (CAGR) of 3.3%. The expansion during the forecast period is predicted to result from increased governmental aid and initiatives, escalating healthcare expenses, a rise in HIV research and development funds, increased HIV incidence rate, enhancing awareness, and economic progression in developing markets. Key trends for the forecast period include investment in 3D bioprinting technology, innovative products, the development of multi-class combination products for treating HIV, and investment in strategic collaborations and agreements.

View the full report here:
https://www.thebusinessresearchcompany.com/report/hiv-drug-global-market-report

What Drivers Are Propelling the Growth of HIV Drugs Market Forward?
The expanding consciousness concerning the detection and treatment of HIV infection serves as a vital catalyst for the development of the HIV medication industry. HIV/AIDS stands out as one of the most persistent ailments, and its widespread occurrence across the globe has led to an unparalleled level of awareness about the disease. Citing an example, the United Nations International Children's Emergency Fund (UNICEF), an American humanitarian aid institution, reported in July 2024 that around 40.0 million people globally were living with HIV in 2023. Out of these, roughly 2.38 million were children aged between 0 and 19. Daily in 2023, an estimated 685 children contracted HIV, and approximately 250 children succumbed to AIDS. Hence, the escalating cognizance amongst the populace regarding the detection and treatment of HIV infection critically fuels the expansion of the HIV medication industry.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2834&type=smp

Which Emerging Trends Are Transforming the HIV Drugs Market in 2025?
Leading firms in the HIV drugs market are collaborating on strategic partnerships to help drive the production of Lenacapavir, expedite its development, broaden its treatment accessibility, and increase their global market footprint. Lenacapavir is a pioneering HIV-1 capsid inhibitor exhibiting its efficacy by targeting various stages of the HIV lifecycle when combined with other antiretrovirals, providing a ray of hope for patients with few treatment options left. For instance, in August 2023, two India-based pharmaceutical giants, Dr. Reddy's Laboratories and Hetero, forged a partnership with Gilead Sciences Inc. The alliance envisages Dr. Reddy's Laboratories and Hetero manufacturing and distributing Lenacapavir in primarily low to lower-middle-income nations, totaling around 120. The motive behind this move is to widen the patient base having access to this path-breaking treatment, which is highly beneficial for patients with multi-drug-resistant HIV. Gilead Sciences Inc. is a renowned biopharmaceutical company based out of the United States.

What Are the Key Segments in the HIV Drugs Market?
The hiv drugs market covered in this report is segmented -

1) By Type: Nucleoside Reverse Transcriptase Inhibitors (NRT's), Non- Nucleoside Reverse Transcriptase Inhibitors (NNRT's), Protease Inhibitors, Integrase strand transfer inhibitors (INSTIs), Other Types
2) By Administration: Oral, Parenteral
3) By Application: Hospital Pharmacies, Retail Pharmacies, Other Applications

Subsegments:
1) By Nucleoside Reverse Transcriptase Inhibitors (NRTIs): Zidovudine (AZT), Lamivudine (3TC), Abacavir (ABC), Tenofovir disoproxil fumarate (TDF), Other NRTIs
2) By Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Efavirenz (EFV), Nevirapine (NVP), Etravirine (ETR), Rilpivirine (RPV), Other NNRTIs
3) By Protease Inhibitors (PIs): Ritonavir (RTV), Lopinavir (LPV), Darunavir (DRV), Atazanavir (ATV), Other PIs
4) By Integrase Strand Transfer Inhibitors (INSTIs): Raltegravir (RAL), Dolutegravir (DTG), Bictegravir (BIC), Other INSTIs
5) By Other Types: Entry Inhibitors, Fusion Inhibitors, Combination Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=2834&type=smp

Who Are the Key Players Shaping the HIV Drugs Market's Competitive Landscape?
Major companies operating in the HIV drugs market include Gilead Sciences Inc., Johnson & Johnson, Merck & Co. Inc., Boehringer Ingelheim International GmbH, Cipla, Aurobindo Pharma, AbbVie, Emcure Pharmaceuticals, Micro Labs Limited, Northeast Pharmaceutical Group Co. Ltd, Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd, Strides Arcolab Limited, Hetero Labs Limited, Shanghai Desano Bio-pharmaceutical Co., Anhui Biochem Biopharmaceutical Co. Ltd., China's National Health Commission (NHC), Shanghai Xinxing Medicine Co. Ltd., China Meheco Xinxing Pharma Co. Ltd., CytoDyn Inc., Janssen Pharmaceutical, Bavarian Nordic, Roche Laboratories, Pharmstandard, Pharmasyntez, R-Pharm, Alium, ChemRar Group, Gritstone Oncology, Enzolytics Inc., BioClonetics Immunotherapeutics Inc., Dewpoint Therapeutics, Lyndra Therapeutics, Mylan N.V., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Teva Canada, ViiV Healthcare Canada, GSK, Abbott Laboratories, Aspen Pharmacare Limited, Pharmacare Ltd.

What Geographic Markets Are Powering Growth in the HIV Drugs Market?
North America was the largest region in the HIV drugs market share in 2024. Middle East is expected to be the largest growing region in the global HIV drug market during the forecast period. The regions covered in the HIV drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2834

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267
Email:saumyas@tbrc.info
The Business Research Company -www.thebusinessresearchcompany.com
Follow Us On:
LinkedIn:https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.